{"meshTags":["Antigens, CD30","Antineoplastic Agents","Hodgkin Disease","Humans","Immunoconjugates","Neoplasm Recurrence, Local"],"meshMinor":["Antigens, CD30","Antineoplastic Agents","Hodgkin Disease","Humans","Immunoconjugates","Neoplasm Recurrence, Local"],"genes":["CD30"],"publicationTypes":["Journal Article"],"title":"Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French Name Patient Program experience in 241 patients.","pubmedId":"25768991"}